Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Searching for Molecules that Slow Parkinson’s Disease Progression
Clinical Breakthroughs

Searching for Molecules that Slow Parkinson’s Disease Progression

By Nora DunneAug 5, 2015
Share
Facebook Twitter Email
Tanya Simuni, MD
“Finding neuroprotective interventions for neurodegenerative diseases is an area of much need and our greatest challenge,” said Tanya Simuni, MD, Parkinson’s Disease and Movement Disorders Center, and principal investigator of this study.

A clinical study led by Northwestern Medicine scientist Tanya Simuni, MD, has crossed a promising compound off the list of potential agents that may slow the progression of Parkinson’s disease.

Previous preclinical work showed that the compound, an FDA-approved drug called pioglitazone currently used to treat diabetes, has neuroprotective effects in animal models of Parkinson’s disease. But the phase two clinical study, published in Lancet Neurology, found that those disease-modifying effects do not translate to patients.

“It’s not enough to demonstrate that the drug is neuroprotective in animal models,” said Dr. Simuni, director of the Parkinson’s Disease and Movement Disorders Center. “You need to demonstrate that the effect can be achieved in humans at doses that are safe to be administered to patients.”

In the study, conducted by National Institute of Neurological Disorders and Stroke (NINDS) Neuroprotection Exploratory Trials of Parkinson’s Disease program, 210 patients recently diagnosed with Parkinson’s disease were randomly assigned to take one of two different doses of pioglitazone or a placebo for 44 weeks. Progression of their disease was measured using the most common Parkinson’s assessment, the Unified Parkinson Disease Rating Scale. Neither dose of pioglitazone slowed progression of disability compared to the placebo.

The study was designed not to definitively prove the effectiveness of the drug for Parkinson’s disease, but rather to determine whether additional trials should continue to test the compound.

“Asking this reverse question – is this molecule considered futile? – is more efficient than recruiting a large sample to answer the efficacy question in the phase two study,” Dr. Simuni said.

Indeed, the investigators do not recommend that scientists continue to pursue pioglitazone as a Parkinson’s disease treatment.

Why Preclinical Findings Didn’t Translate

Pioglitazone is not the first molecule to fail in a Parkinson’s disease clinical study despite rigorous tests showing promise in preclinical trials. Multiple reasons explain this, said Dr. Simuni. First, animal models are not ideal reflections of real Parkinson’s disease in human patients.

“Animal models are created to represent the clinical picture as best as we can,” she said. “We need better models.”

Second, patients may not have been exposed to a sufficient dose of the drug to experience its potential benefits.

“Within the safety parameters, we went as high as we could have gone,” Dr. Simuni said.

Third, the drug intervention may be coming too late in the disease process to help. By the time patients present symptoms and are diagnosed with Parkinson’s, they have already lost 70 percent of the brain cells that produce dopamine.

“The silver lining is that while the results are quite disappointing, this study is an example of an efficient phase two study that gave us a definitive answer about this molecule. We’re not left with a ‘maybe,’” Dr. Simuni said.

Though pioglitazone is off the list, there’s evidence that other molecules in the glitazone family of diabetes drugs may still help patients with Parkinson’s disease.

“The only way we will find efficacious molecules is to continue testing the drugs that have been best characterized in preclinical trials,” Dr. Simuni said. “The odds are against us statistically, but we as a scientific community are determined to win this battle.”

Dr. Simuni is the Arthur C. Nielsen, Jr. Research Professor in Parkinson’s Disease and Movement Disorders in the Ken and Ruth Davee Department of Neurology.

This study was funded by the NINDS.

Neurology and Neuroscience Research
Share. Facebook Twitter Email

Related Posts

Coaxing Hair Growth in Aging Hair Follicle Stem Cells

Jun 9, 2023

New Therapeutic Target for Osteoarthritis Identified 

Jun 9, 2023

Largest Cell Map of Human Lung Reveals Insights Into Disease

Jun 8, 2023

Comments are closed.

Latest News

Coaxing Hair Growth in Aging Hair Follicle Stem Cells

Jun 9, 2023

New Therapeutic Target for Osteoarthritis Identified 

Jun 9, 2023

Largest Cell Map of Human Lung Reveals Insights Into Disease

Jun 8, 2023

McNally Honored with Walder Award

Jun 8, 2023

Biological Aging Increases Risk of Depression, Anxiety in Adults 

Jun 7, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
ANB05555
ANB08990
ANB09022
ANB09063
ANB09008
ANB08781
ANB08971
ANB09000
ANB08992
ANB09015
ANB09058
ANB09048

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.